22 December 2017
Grant Instruments is pleased to announce the appointment of Non-Executive Directors Dr Mike Evans and Dr Chris Lowe
Dr Mike Evans is Chief Executive at Oxford Gene Technology (OGT), where he has led the transformation from a licensing business model to a highly successful genomic products business and negotiated the sale of the company to Sysmex Corporation in June 2017.
Before joining OGT, Mike held a number of senior positions at GE Healthcare/Amersham Biosciences, including Executive Vice President, Marketing and Strategy and Executive Vice President, Corporate Development. Mike was Managing Director, Fine Chemicals at Ascot plc, prior to the sale of Ascot to Dow Chemical. Mike has also held several non-executive directorships and was chairman of TAP Biosystems Group plc until its sale to Sartorius Stedim Biotech. Mike holds a BA, MA and DPhil from the University of Oxford.
Dr Chris Lowe received his BA Hons degree and DPhil in Chemistry from the University of Oxford. After a period of postdoctoral research at the University of Alberta, Canada, he returned to the UK in 1994 to work as a medicinal chemist with the biotechnology company Chiroscience, later acquired by Celltech and subsequently by UCB. He moved into business management with Cancer Research Technology, then in 2009 took up a position as Senior Technical Officer at the Department of Chemistry, University of Cambridge, where he is responsible for the operational management of the research group of Professor Sir Shankar Balasubramanian.